DOCSLIB.ORG

Psychotic Disorder Due to Withdrawal of Barbexaclone Barbeksaklon Yoksunluğuna Bağlı Psikotik Bozukluk

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Psychotic Disorder Due to Withdrawal of Barbexaclone Barbeksaklon Yoksunluğuna Bağlı Psikotik Bozukluk Letter to the Editor 87 DOI: 10.4274/Npa.y 6310 Psychotic Disorder due to Withdrawal of Barbexaclone Barbeksaklon Yoksunluğuna Bağlı Psikotik Bozukluk Murat KULOĞLU1, Sevda KORKMAZ2, Sadullah SAĞLAM3, Murad ATMACA1 1Fırat University Hospital Psychiatry Clinic, Elazığ, Turkey 2Elazığ Psychiatry Hospital, Psychiatry Clinic, Elazığ, Turkey 3Elazığ Psychiatry Hospital, Neurology Clinic, Elazığ, Turkey Dear Editor, which became generalized. He had approximately 3-4 seizures a year. It was learned that the patient who had these complaints Barbexaclone (Maliasin®) is an antiepileptic drug which is for the last three days discontinued barbexaclone two days composed of phenobarbital and salt compound of before the onset of the symptoms. Epileptic seizure was not propylhexedrine which is known to be a central nervous system described in the initial period of the complaints. The patient who stimulant . It has been reported that psychotic symptoms may had no previous history of psychiatric disease had no physical rarely develop during treatment with phenobarbital and other illness except for epilepsy. Complete blood count, biochemical antiepileptic drugs (1). Although there are case reports in the tests and thyroid function tests were within normal limits. On literature about development of addiction with barbexaclone (2), neurological examination, his consciousness was open, he had there is no information about development of psychotic disorder full orientation to place, time and person. However, full with discontinuance after long-term use. In our article, we aimed cooperation could not be established with the patient because of to present a patient who developed psychotic symptoms and active psychotic symptoms. The patient had disarthric speech. some behavioral changes with sudden discontinuance of On psychiatric examination, it was observed that he had barbexaclone. intermittent agitations, paranoid thoughts and delusions of M.K 38-year-old, married, has three children, primary school persecution. The diagnosis of delirium was excluded, since graduate male patient. He presented to the emergency orientation to place, time and person in the patient was complete department with complaints including nervousness, peculiar on examination of orientation performed during the periods speech and behavior, tendency to harm himself and his relatives, when delusions and hallucinations were present. No sensibility and suspiciousness. According to the information pathological finding was found on brain magnetic resonance obtained from his family, the patient had these complaints for the imaging and electroencephalography (EEG). Personality test last three days. He tried to burn his house a few hours ago, broke could not be performed, since the patient was not cooperated. the glasses of the cars in the district and was brought to our Amisulpride 200 mg/day was started considering ‘’Psychotic clinic by the police, since he did not accept treatment. He had no disorder related to use of psychoactive substance’’ (progressing communication with his environment for approximately 20 years. with delusions-starting at the time of discontinuance) according He used barbexaclone 100 mg/day and carbamazepine 800 to the American Psychiatry Association, Mental Disorders mg/day for treatment of complex partial seizures accompanied Diagnostic and Statistical Manual IV-TR (3) because of the fact by meaningless walking and mouth-tongue automatisms some of that there was no secondary factor explaining the condition Cor res pon den ce Ad dress/Ya z›fl ma Ad re si: Murat Kuloğlu MD, Fırat University Hospital Psychiatry Clinic, Elazığ, Turkey Gsm: +90 533 413 98 97 E-mail: [email protected] Re cei ved/Ge lişta ri hi: 14.09.2011 Ac cep ted: 24.03.2012 © Arc hi ves of Neu ropsy chi atry, pub lis hed by Ga le nos Pub lis hing. / © Nö rop si ki yat ri Ar şi vi Der gi si, Ga le nos Ya yı ne vi ta ra f›n dan ba s›l m›fl t›r. 88 Kuloğlu et al. Arc hi ves of Neu ropsy chi atry 2013; 50: 87-88 Psychotic Disorder due to Withdrawal of Barbexaclone Nö rop si ki yat ri Ar fli vi 2013; 50: 87-88 except for the drug he used and the information obtained from to abuse especially drugs which are effective on the central his history. Carbamazepine 800 mg/day which he used as nervous system. It is thought that the property of barbexaclone antiepileptic treatment was continued. Diazepam 15 mg/day was which leads to off label use of the drug arises from its sedative or added considering the risk of epileptic seizure and phenobarbital anxiolytic effect (2). It has been reported that the reason that withdrawal symptoms. Withdrawal symptoms were not antiepileptic addiction does not develop in epileptic patients is observed during the follow-up period of approximately 1 month. the fact that the expectations related with the drug are related Laboratory tests were within normal limits. During the following with the anticonvulsant effect rather than the psychotropic follow-up period of 6 months, no precursor, residual or psychotic effect (9). symptom was observed. Conclusively, considering the fact that sudden Although psychosis picture is frequently observed in the discontinuance of barbexaclone which is known to have an course of epilepsy, the fact that no epileptic seizure was addiction potential (10) may be related with psychotic process described before the psychotic attack, epileptiform activity was and the physician’s attention in terms of psychotic disorder or not observed on EEG recordings, the patient had no previous similar psychiatric side effects while using antiepileptic drugs history of psychotic attack and responded to antipsychotic will be beneficial in the diagnosis and treatment. treatment better and experienced the attack following sudden discontinuation of barbexaclone suggested that the psychotic References picture might be related with sudden discontinuation of the drug rather than psychosis which may be observed during the course 1. Lancman M. Psychosis and peri-ictal confusional states. Neurology 1999; of epilepsy. 53:33-38. 2. Sezgin E, Evren C, Çınar ÖG, Küçükgöncü S, Kılıç Bayram M. Antiepileptik, Neuropsychiatric symptoms may be observed in relation Barbeksaklon (Maliasin®) bağımlılığı olan iki olgu. Düşünen Adam with antiepileptic drugs. Although barbexaclone is a drug which Psikiyatri ve Nörolojik Bilimler Dergisi 2010; 23:128-132. is as efficient as phenobarbital and tolerated better, it carries a 3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth ed. Text revision (DSM-IV-TR). Washington: APA, risk of addiction in terms of propylhexedrine which is the other 2000. component of the drug and its abuse is observed because of its 4. Darcın AE, Dilbaz N, Okay IT. Barbexaclone abuse in a cannabis ex-user. amphetamine-like stimulant effect and structural similarity (4). In Subst Abus 2010; 31:270-272. the literature, sudden death (5), soft tissue demage (6) and brain 5. Anderson RJ, Garza HR, Garriott JC, Dimaio V. Intravenous prophylhexedrine (Benzedrex) abuse and sudden death. Am J Med 1979; stem involvement characterized with diplopia (7) have been 67:15-20. reported with propylhexedrine. In addition, cases of addiction 6. Mancusi-Ungaro HR Jr, Decker WJ, Forshan VR, Blackwell SJ, Lewis SR. have been described with use of barbexaclone. Darçin et al. (4) Tissue injuries associated with parenteral propylhexedrine abuse. J Toxicol Clin Toxicol 1983-1984; 21:359-372. reported use of barbexaclone with the aim of relaxation in a 7. Fornazzari L, Carlen PL, Kapur BM. Intravenous abuse of propylhexedrine patient who was an old cocaine user. Sezgin et al. (2) presented (Benzedrex) and the risk of brainstem dysfunction in young adults. Can J two patients who were diagnosed with barbexaclone abuse for Neurol Sci 1986; 13:337-339. the aim of calming down and relaxation and barbexaclone 8. Yaris F, Kadioglu M, Kesim M, Ulku C, Yaris E, Kalyoncu NI. Barbexaclone use in pregnancy. Saudi Med J 2004; 25:245-246. addiction. Unlike these negative effects, Yaris et al. (8) reported 9. Uhlmann C, Fröscher W. Low risk of development of substance dependence that no teratogenic effect was observed in the infant of a mother for barbiturates and clobazam prescribed as antiepileptic drugs: results who used barbexaclone during pregnancy unwittingly. from a questionnaire study. CNS Neurosci Ther 2009; 15:24-31. 10. Torta R, Keller R. Behavioral, psychotic, and anxiety disorders in epilepsy: It has been recognized that individuals who have a etiology, clinical features, and therapeutic implications. Epilepsia 1999; 40 personal or familial history of substance abuse have a tendency (Suppl 10):2-20..
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Barbexaclone Use in Pregnancy Oxcarbazepine During the Breast Feeding Period
    Age of menarche in Jordanian girls Acknowledgment. We are grateful to Dr. M. A 36-year-old caucasian woman, multigravida Ammari in collecting the data. case had begun to use barbexaclone 300 mg/day and oxcarbazepine 600 mg/day, for 2 years before the Received 10th June 2003. Accepted for publication in final form 13th September 2003. pregnancy, due to epilepsy and continued to use both drugs until the end of week 10 of her From the Department of Medicine, Jordan University of Science and pregnancy. When she became aware of pregnancy, Technology, Irbid, Jordan. Address correspondence and reprint requests to Dr. Fawaz Ammari, Department of Medicine, Jordan she decided to quit taking barbexaclone with our University of Science and Technology, PO Box 3030, Irbid 22110, recommendation, as there was no data regarding this Jordan. Tel/Fax. +962 (2) 7095010. E-mail: dr_fammari@hotIntroduction drug regarding human or animal pregnancy. Oxcarbazepine 1200 mg/day was continued until the References end of pregnancy. She did not use folic acid before or during the pregnancy. No clinical worsening in 1. Saar E, Shalev C, Dalal I, Sod-Moriah UA. Age at epilepsy was observed after withdrawal of menarche: The influence of environmental condition. Int J barbexaclone. She had a history of one therapeutic Biometeorol 1988; 32: 33-35. 2. Manniche E. Age at menarche: Nicolai Edvard Ravn’s data abortion due to carbamazepine use and one on 3385 women in mid-19th century Denmark. Ann Hum spontaneous abortion. All obstetrical and Biol 1983; 10: 79-82. ultrasonographical findings of the present pregnancy 3.
    [Show full text]
  • Toxic, and Comatose-Fatal Blood-Plasma Concentrations (Mg/L) in Man
    Therapeutic (“normal”), toxic, and comatose-fatal blood-plasma concentrations (mg/L) in man Substance Blood-plasma concentration (mg/L) t½ (h) Ref. therapeutic (“normal”) toxic (from) comatose-fatal (from) Abacavir (ABC) 0.9-3.9308 appr. 1.5 [1,2] Acamprosate appr. 0.25-0.7231 1311 13-20232 [3], [4], [5] Acebutolol1 0.2-2 (0.5-1.26)1 15-20 3-11 [6], [7], [8] Acecainide see (N-Acetyl-) Procainamide Acecarbromal(um) 10-20 (sum) 25-30 Acemetacin see Indomet(h)acin Acenocoumarol 0.03-0.1197 0.1-0.15 3-11 [9], [3], [10], [11] Acetaldehyde 0-30 100-125 [10], [11] Acetaminophen see Paracetamol Acetazolamide (4-) 10-20267 25-30 2-6 (-13) [3], [12], [13], [14], [11] Acetohexamide 20-70 500 1.3 [15] Acetone (2-) 5-20 100-400; 20008 550 (6-)8-31 [11], [16], [17] Acetonitrile 0.77 32 [11] Acetyldigoxin 0.0005-0.00083 0.0025-0.003 0.005 40-70 [18], [19], [20], [21], [22], [23], [24], [25], [26], [27] 1 Substance Blood-plasma concentration (mg/L) t½ (h) Ref. therapeutic (“normal”) toxic (from) comatose-fatal (from) Acetylsalicylic acid (ASS, ASA) 20-2002 300-3502 (400-) 5002 3-202; 37 [28], [29], [30], [31], [32], [33], [34] Acitretin appr. 0.01-0.05112 2-46 [35], [36] Acrivastine -0.07 1-2 [8] Acyclovir 0.4-1.5203 2-583 [37], [3], [38], [39], [10] Adalimumab (TNF-antibody) appr. 5-9 146 [40] Adipiodone(-meglumine) 850-1200 0.5 [41] Äthanol see Ethanol -139 Agomelatine 0.007-0.3310 0.6311 1-2 [4] Ajmaline (0.1-) 0.53-2.21 (?) 5.58 1.3-1.6, 5-6 [3], [42] Albendazole 0.5-1.592 8-992 [43], [44], [45], [46] Albuterol see Salbutamol Alcuronium 0.3-3353 3.3±1.3 [47] Aldrin -0.0015 0.0035 50-1676 (as dieldrin) [11], [48] Alendronate (Alendronic acid) < 0.005322 -6 [49], [50], [51] Alfentanil 0.03-0.64 0.6-2.396 [52], [53], [54], [55] Alfuzosine 0.003-0.06 3-9 [8] 2 Substance Blood-plasma concentration (mg/L) t½ (h) Ref.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • CEL MAI KO NA NA NA NA NA (12 ) United States Patent ( 10 ) Patent No
    US010064856B2CEL MAI KO NA NA NA NA NA (12 ) United States Patent ( 10 ) Patent No. : US 10 , 064 ,856 B2 Bosse et al. ( 45 ) Date of Patent: * Sep . 4 , 2018 ( 54 ) PHARMACEUTICAL COMPOSITIONS (52 ) U .S . CI. ??? . .. A61K 31/ 485 ( 2013 .01 ) ; A61K 9 / 209 @(71 ) Applicant : LOCL PHARMA , INC . , Las Vegas , ( 2013 . 01 ) ; A61K 9 / 2013 ( 2013 . 01 ) ; A61K NV ( US ) 9 /2027 ( 2013 .01 ) ; A61K 9 / 2054 ( 2013 .01 ) ; A61K 9 / 4808 ( 2013 .01 ) ; A61K 31 / 165 @(72 ) Inventors : Paul Bosse, Jupiter , FL (US ) ; John ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Ameling , Jupiter, FL (US ) ; Bernard 31/ 24 ( 2013 .01 ) ; A6IK 31/ 403 ( 2013 .01 ) ; Schachtel, Jupiter, FL (US ) ; Ray A61K 31/ 404 (2013 .01 ) ; A61K 31 /4196 Takigiku , Loveland , OH (US ) ( 2013 . 01 ) ; A61K 31/ 422 ( 2013 . 01 ) ; A61K 31 / 437 ( 2013 .01 ) ; A61K 31/ 454 ( 2013 .01 ) ; @( 73 ) Assignee : LOCAL PHARMA , INC ., Las Vegas , A61K 31 /515 ( 2013 . 01 ) ; A61K 31/ 522 ( 2013 . 01 ) ; A61K 31 /5415 ( 2013 .01 ) ; A61K NV (US ) 45 / 06 ( 2013 .01 ) ; A61K 9 / 0024 ( 2013 .01 ) ; @( * ) Notice : Subject to any disclaimer , the term of this A61K 9 / 0056 ( 2013 . 01 ) ; A61K 9 / 1694 patent is extended or adjusted under 35 ( 2013 . 01 ) ; A61K 9 /2086 ( 2013 . 01 ) ; A61K U . S . C . 154 (b ) by 0 days . 47 / 36 ( 2013 .01 ) (58 ) Field of Classification Search This patent is subject to a terminal dis None claimer . See application file for complete search history . ( 21 ) Appl. No .: 15 / 683, 635 ( 56 ) References Cited ( 22 ) Filed : Aug . 22, 2017 U . S . PATENT DOCUMENTS 3 ,048 , 526 A 8 / 1962 Boswell (65 ) Prior Publication Data 3 , 108 , 046 A 10 / 1963 Harbit 3 , 536 ,809 A 10 / 1970 Norman US 2017 /0348303 A1 Dec .
    [Show full text]
  • Pharmaceutical Composition with Synergistic Anticonvulsant Effect
    (19) TZZ __T (11) EP 2 695 618 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 12.02.2014 Bulletin 2014/07 A61K 38/04 (2006.01) A61P 21/00 (2006.01) A61P 19/00 (2006.01) A61P 25/14 (2006.01) (2006.01) (21) Application number: 13004798.8 A61K 31/40 (22) Date of filing: 15.06.2007 (84) Designated Contracting States: (71) Applicant: UCB Pharma GmbH AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 40789 Monheim (DE) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (72) Inventor: Stöhr, Thomas 2400 Mol (BE) (30) Priority: 15.06.2006 US 813967 P 12.10.2006 EP 06021470 (74) Representative: Dressen, Frank 12.10.2006 EP 06021469 UCB Pharma GmbH 22.11.2006 EP 06024241 Alfred-Nobel-Strasse 10 40789 Monheim (DE) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: Remarks: 07764676.8 / 2 037 965 This application was filed on 04-10-2013 as a divisional application to the application mentioned under INID code 62. (54) PHARMACEUTICAL COMPOSITION WITH SYNERGISTIC ANTICONVULSANT EFFECT (57) The present invention is directed to a pharmaceutical composition comprising (a) lacosamide and (b) levetira- cetam for the prevention, alleviation or/and treatment of epileptic seizures. EP 2 695 618 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 695 618 A1 Description [0001] The present application items the priorities of US 60/813.967 of 15 June 2006, EP 06 021 470.7 of 12 October 2006, EP 06 021 469.9 of 12 October 2006, and EP 06 024 241.9 of 22 November 2006, which are included herein by 5 reference.
    [Show full text]